DAVID GRANOVSKY

Posts Tagged ‘cord’

PANCREATIC CANCER TUMORS DEFEATED WITH CORD BLOOD STEM CELLS

In ALL ARTICLES, SCIENCE & STEM CELLS, VICTORIES & SUCCESS STORIES on June 25, 2014 at 11:42 am

fight pancreatic cancer FPC_shirt


PANCREATIC CANCER TUMORS DEFEATED WITH CORD BLOOD STEM CELLS

What happens when you “genetically engineer MSCs isolated from human umbilical cord blood so that they expressed IL-15” (which fights cancer tumors) and inject them into mice with pancreatic  tumors?

  • The IL-15 migrate to the tumor
  • Other cancer and tumor fighting immune cells migrate to the tumor
  • The IL-15 attack the tumor
  • Other cancer and tumor fighting immune cells attack the tumor
  • Tumors show cell death
  • Tumor growth is significantly inhibited
  • Survival is prolonged
  • The mice immune systems are effectively vaccinated against future tumor growth

Scientists “used these souped-up cells to treat In mice afflicted with pancreatic tumors. Pancreatic cancer is an indiscriminate killer, since by the time it causes any symptoms, it is usually so advanced, that there is little to be done in order to treat it. Thus new strategies to treat this type of cancer are eagerly being sought. Systemic administration of IL-15-expressing MSCs significantly inhibited tumor growth and prolonged the survival of tumor-bearing mice. The tumors of these mice showed extensive cell death, and other types of immune cells known to fight tumor cells (NK and T cells) had also accumulated around the tumor. Other experiments confirmed that the injected MSCs did indeed migrate toward the tumors and secrete IL-15 at the site of the tumors…Interestingly, those mice that were cured from the pancreatic tumors, appeared to have a kind of resistance of these tumors. Namely, when Fan and his colleagues tried to reintroduce the same tumor cells back into the cured mice, the tumor cells would not grow. Thus the engineered MSCs not only tuned the immune system against the tumor, but they effectively vaccinated the mice against it as well.”

via http://beyondthedish.wordpress.com/2014/06/23/engineered-stem-cels-from-human-umbilical-cord-blood-eradicates-pancreatic-tumor/

 

 

Thanks Squeeky!

mouse-grown-from-stem-cells

ROUND UP DAMAGES EMBRYONIC, PLACENTAL AND UMBILICAL CORD CELLS

In ALL ARTICLES, OFF THE BEATEN PATH, STEM CELLS IN THE NEWS on June 20, 2014 at 12:23 pm

roundup-the-ultimate-killing-machine

ROUND UP DAMAGES EMBRYONIC, PLACENTAL AND UMBILICAL CORD CELLS

Chemicals in Round Up are targeting both our reproductive abilities and our regenerative/healing abilities.  But we’ve know this for a long time.  What’s special about this article is that it is in Scientific American, “The leading source and authority for science, technology information and policy for a general audience”

From the article:
“Monsanto scientists argue that cells in Seralini’s study were exposed to unnaturally high levels of the chemicals…Seralini’s team, however, did study multiple concentrations of Roundup. These ranged from the typical agricultural or lawn dose down to concentrations 100,000 times more dilute than the products sold on shelves. The researchers saw cell damage at all concentrations.”

So while Monsanto scientists say the study used unnaturally high amounts, this is false,  The study included samples 100,000 TIMES MORE DILUTE than average exposures AND IT STILL CAUSED CELL DAMAGE.

Cell damage to

  • EMBRYONIC CELLS
  • PLACENTAL CELLS
  • UMBILICAL CORD CELLS

The corner stone to both our reproductive and regenerative capabilities.  Think you’re safe? - Roundup Weedkiller Found In 75% of Air and Rain Samples, Gov. Study Finds

You idiots.  You’ve killed us all.

statue_planet

http://www.scientificamerican.com/article/weed-whacking-herbicide-p/

Stem Cell Transplantation in Traumatic Spinal Cord Injury

In STEM CELLS IN THE NEWS on January 23, 2014 at 5:59 pm

Stem Cell Transplantation in Traumatic Spinal Cord Injury: A Systematic Review and Meta-Analysis of Animal Studies

http://www.accesssportsmed.com/wp-content/uploads/2011/03/spine_large.jpg

From http://www.plosbiology.org – January 6, 7:09 AM

Spinal cord injury is an important cause of disability in young adults, and stem cells have been proposed as a possible treatment. Here we systematically assess the evidence in the scientific literature for the effectiveness of stem-cell–based therapies in animal models of spinal cord injury.

Ella Buzhor\’s insight:

The comparison between multiple allogeneic stem cell treatments revealed improved both motor and sensory function in SCI animal models. Differentiation prior to implantation and IV route of cell administration yielded better outcomes.

via Cell Therapy & Regenerative Medicine | Scoop.it.

FDA-Regulated Study of Cord Blood Stem Cells to Treat Acquired Hearing Loss Launches

In SCIENCE & STEM CELLS, STEM CELLS IN THE NEWS on January 17, 2014 at 9:20 am

hearing loss

PR Newswire

SAN BRUNO, Calif., Jan. 16, 2014

Signals Potential of Newborn Stem Cells in Regenerative Medicine for Common Disorders

SAN BRUNO, Calif., Jan. 16, 2014 /PRNewswire-USNewswire/ – Cord Blood Registry® (CBR®), the world’s largest and most experienced newborn stem cell company, announces the start of a U.S. Food and Drug (FDA)-regulated study being conducted at Florida Hospital for Children in Orlando to investigate the use of a child’s stem cells from their own stored umbilical cord blood as a treatment for acquired sensorineural hearing loss.

(Logo: http://photos.prnewswire.com/prnh/20131216/DC33657LOGO-a)

In the United States, approximately 15 percent of children suffer from low or high-frequency hearing loss.[i] The most common type of hearing loss, especially at high frequencies, is sensorineural. Acquired sensorineural hearing loss results from damage to hair cells in the inner ear (cochlea) and can be caused by illness, medication, noise exposure, birth injury, or head trauma. A child’s ability to hear affects the development of language skills, and hearing impairments can lead to poor academic and social development.[ii]

The groundbreaking phase 1 study has a primary objective of determining the safety of using cord blood stem cells in a select pediatric patient population while also assessing whether this approach to treatment improves inner ear function, speech, and language development. Researchers will follow 10 children, ranging in age from 6 weeks to 6 years, who have been diagnosed with acquired hearing loss for less than 18 months and who have their own cord blood unit processed and stored under CBR’s strict quality controls. Children with a known genetic cause of deafness are ineligible for study participation. Patients will receive one intravenous infusion of their own umbilical cord blood stem cells. All patients will return for follow-up at 1 month, 6 months, and 1 year post-treatment.

The trial, supported by CBR, follows promising evidence from preclinical studies suggesting that the infusion of human umbilical cord stem cells may help repair damaged cells in the inner ear in ways that could lead to hearing improvement.[iii]

“As more children survive premature birth, we are observing increasing numbers of very young children with significant acquired hearing loss, and currently there are no therapies available for reversing that damage,” says Linda Baumgartner M.S., CCC-SLP, LSLS cert. AVT, the trial’s Speech and Language Pathologist and hearing loss expert.  James Baumgartner, MD, Surgical Director of Florida Hospital for Children’s Comprehensive Pediatric Epilepsy Center and the study’s principal investigator notes that “presently, the only treatment options for acquired sensorineural hearing loss are hearing aids or cochlear implants, neither of which actually repairs the damage. Using cord blood stem cells to help trigger the body’s own repair mechanisms could provide a non-invasive therapeutic option that does not exist today.”

During the last 25 years, cord blood stem cells have been used in more than 30,000 transplants performed worldwide for the treatment of nearly 80 serious diseases and disorders in both adults and children. The evolution of stem cell therapies has paved the way for further research being conducted through FDA-regulated clinical trials to uncover their potential in regenerative medicine applications.

“Cord Blood Registry continues to lead the industry in evaluating the potential of newborn stem cells in neurological damage, supporting FDA-regulated clinical trials in autism, cerebral palsy, pediatric stroke, traumatic brain injury, and now hearing loss,” underscores Heather Brown, Vice President of Scientific & Medical Affairs at CBR. “We are excited to learn from the outcomes of this particular study and from future studies that may evaluate broader populations affected by hearing loss or other neurological impairments for which there are limited treatment options today,” adds Brown.

For further details regarding the study, visit www.cordblood.com/hearingloss

About Cord Blood Registry

Cord Blood Registry® (CBR®) is the world’s largest newborn stem cell company. Founded in 1992, CBR is entrusted by parents with storing more than 500,000 cord blood and cord tissue units. CBR is dedicated to advancing the clinical application of newborn stem cells by partnering with leading research institutions to establish FDA-regulated clinical trials requiring CBR processed cord blood for conditions that have no cure today. For more information, visit www.cordblood.com

Florida Hospital for Children
Florida Hospital for Children is a full-service facility served by more than 130 pediatric specialists and a highly trained pediatric team of more than 1,000 caregivers and staff. This unique children’s hospital provides patients with private, family-centered pediatric rooms, a dedicated pediatric emergency department and an Advanced Center for Pediatric Surgery. The Walt Disney Pavilion at Florida Hospital for Children, in Orlando, delivers a complete range of pediatric health and research services for younger patients including advanced surgery, oncology, neurosurgery, cardiology and transplant services, full-service pediatrics, and an innovative health and obesity platform. The 200-pediatric bed facility officially opened in March 2011, but Florida Hospital has been caring for children for more than 100 years.

Contact Information:
Brian Plummer
Manager, Public Relations & Corporate Communications
(650) 635-1420 | EXT. 255
BPlummer@cordblood.com

[i] Niskar, AS, et al. Prevalence of hearing loss among children 6 to 19 years of age: the Third National Health and Nutrition Examination Survey. JAMA.1998;279:1071-1075.

[ii] Tierney, CD, et al. Development of children who have hearing impairment. Pediatr Rev 29, e72-73; discussion e73 (2008)

[iii] Revoltella RP, Papini S, Rosellini A, et al. Cochlear repair by transplantation of human cord blood CD133+ cells to nod-scid mice made deaf with kanamycin and noise. Cell Transplant.2008;17(6):665-678.

SOURCE Cord Blood Registry

SCIENCE FICTION COMES ALIVE WITH ORGANS GROWN IN A LAB

In SCIENCE & STEM CELLS, STEM CELLS IN THE NEWS on March 26, 2013 at 9:00 am

032213bodyparts2_512x288

Building a complex human organ in the lab is no longer a dream of science fiction. At London’s Royal Free Hospital, a team of 30 scientists is manufacturing a variety of body parts, including windpipes, noses and ears. WSJ’s Gautam Naik reports. Photo: Gareth Phillips

Science Fiction Comes Alive as Researchers Grow Organs in Lab

MADRID—Reaching into a stainless steel tray, Francisco Fernandez-Aviles lifted up a gray, rubbery mass the size of a fat fist.  It was a human cadaver heart that had been bathed in industrial detergents until its original cells had been washed away and all that was left was what scientists call the scaffold.  Next, said Dr. Aviles, “We need to make the heart come alive.”

Inside a warren of rooms buried in the basement of Gregorio Marañón hospital here, Dr. Aviles and his team are at the sharpest edge of the bioengineering revolution that has turned the science-fiction dream of building replacement parts for the human body into a reality.  Since a laboratory in North Carolina made a bladder in 1996, scientists have built increasingly more complex organs. There have been five windpipe replacements so far. A London researcher, Alex Seifalian, has transplanted lab-grown tear ducts and an artery into patients. He has made an artificial nose he expects to transplant later this year in a man who lost his nose to skin cancer.

“The work has been extraordinarily pioneering,” said Sir Roy Calne, an 82-year-old British surgeon who figured out in the 1950s how to use drugs to prevent the body from rejecting transplanted organs.

Now, with the quest to build a heart, researchers are tackling the most complex organ yet. The payoff could be huge, both medically and financially, because so many people around the world are afflicted with heart disease. Researchers see a multi billion dollar market developing for heart parts that could repair diseased hearts and clogged arteries.

In additional to the artificial nose, Dr. Seifalian is making cardiovascular body parts. He sees a time when scientists would grow the structures needed for artery bypass procedures instead of taking a vein from another part the body. As part of a clinical trial, Dr. Seifalian plans to transplant a bio-engineered coronary artery into a person later this year. His employer, University College London, has designated a person to oversee any future commercialization of it and other man-made organs.

The development of lab-built body parts is being spurred by a shortage of organ donors amid rising demand for transplants. Also, unlike patients getting transplants, recipients of lab-built organs won’t have to take powerful anti-rejection drugs for the rest of their lives. That’s because the bio-engineered organs are built with the patients’ own cells.

Until the late 1980s, few scientists believed it would be possible to make human organs because it was a struggle to grow human cells in the laboratory. The task became easier once scientists figured out the chemicals—known as growth factors—that the body itself uses to promote cellular growth.

Scientists started out growing simple organs. In 1999, Anthony Atala, director of the Wake Forest Institute for Regenerative Medicine in Winston-Salem, N.C., implanted lab-grown bladders into the first of several children with severely dysfunctional bladders. The organs have continued to function well for several years. Dr. Atala’s team now is trying to grow a whole range of bio-engineered parts, from simple blood vessels to human livers.

Some of the most complex work is under way at Dr. Seifalian’s laboratory.   A 56-year-old native of Iran, Dr. Seifalian started out as a nuclear physicist, and became interested in medical uses of nuclear technology. That ultimately led him to bioengineering.  In 2011, Dr. Seifalian made a windpipe from a patient’s cells. It was used to replace the cancerous windpipe of the patient, saving his life, his surgeon has said.

Dr. Seifalian and 30 scientists now seek to build a larynx, ears, noses, urethras and bile ducts  Most human organs get their form from an internal scaffolding of collagen and other proteins. Scientists struggled for years to find a replacement material that was strong and flexible and yet wouldn’t be rejected by the bodyEventually, they homed in on a couple of high-tech materials made from plant fibers, resins and other substances. Dr. Seifalian said he uses a material that is modeled on the honeycomb structure of a butterfly’s wing. The material, a so-called nanocomposite, is resistant to infectious bacteria and has pores that are the right size to hold cells.  “The material has to be accepted by the body, but it also has to be easy to manipulate into different shapes, different strengths,” said Dr. Seifalian.

The nose in the jar was closely modeled on the nose of a 53-year-old Briton. With the help of imaging scans and a glass mold designed by an artist, researchers first fabricated a replica of the original nose. The patient was asked if he wanted a slight deviation in his septum to be straightened out, but he turned down the offer, according to Dr. Seifalian.  The researchers poured the material into the artist’s mold. They added salt and sugar. That created holes in the material and gave it a spongy, porous feel, just like the real thing.  The key to all the lab-built organs are stem cells, found in human bone marrow, fat and elsewhere. Stem cells can be transformed into other tissues of the body, making them the basic building blocks for any organ.

In the case of the nose, stem cells extracted from the patient’s fat tissue were added to the artist’s mold, along with chemicals that control cell development. The stem cells sat inside the pores of the lab-made organ and gradually differentiated into cells that make cartilage.  However, the nose was missing a crucial piece: skin.  This posed a substantial hurdle. No one has made natural human skin from scratch. Dr. Seifalian’s idea: to implant the nose under the skin of the patient’s forehead in the hope that skin tissue there would automatically sheath the nose.

 nose-growing-on-arm-omg

But the patient objected, and for good reason: The implanted nose would have to sit inside his forehead for weeks or even months. In the end, Dr. Seifalian chose a less obtrusive approach. The bio-engineered nose was implanted under the patient’s forearm.  The team now is using imaging equipment to keep tabs on whether the necessary blood vessels, skin and cartilage are forming in the right way. “We’ll have to also make sure there’s no infection,” Dr. Seifalian said in late November, on the day of the patient’s surgery.  If the skin graft works, surgeons will remove the nose from the arm and attach it to the patient’s face. Dr. Seifalian will then apply the right chemicals to convert the man’s stem cells into epithelial cells, a common type of tissue found in the nose and in the lining of other organs. The epithelial cells will be inserted into the nose.  As a final step, surgeons will connect blood vessels from the face to the site of the new nose to provide a steady flow of nourishment for the growing cells. “The whole process could take six months,” said Dr. Seifalian. He estimates the cost of making the nose in the lab is about $40,000, but the patient isn’t being charged because the doctors and scientists are either donating their time or working on this as part of their research.

Dr. Seifalian said the new nose could restore some sense of smell to the patient, but its main benefit will be cosmetic. He held up a jar full of early-stage lab-made noses, and another filled with early-stage ears.

“We’re actually in the process of making a synthetic face,” he said. From a cosmetic point of view, “if you can make the ear and the nose, there’s not much left.”  Regenerating a nose would be a striking achievement; creating a complex organ like the heart would be historic. A team led by Spain’s Dr. Aviles is trying to get there first.

Dr. Aviles trained as a cardiologist but became frustrated with the difficulty of treating patients with advanced heart disease. The only option for the worst cases was a heart transplant, and there was a shortage of hearts. Spain has the highest donor rate in the world, yet Dr. Aviles said that only about 10% of patients who need a heart transplant get one.

He was approached in 2009 by a U.S. scientist, Doris Taylor, who had already grown a beating rat heart in the lab while at the University of Minnesota. Instead of using a man-made scaffold, Dr. Taylor had used the scaffolding from an actual rat heart as the starting point. She believed the same technique was crucial for making a working human heart. She was attracted to Spain because the higher donor rate meant that more hearts unsuitable for transplant could be used for experiments.

Dr. Aviles and about 10 colleagues began their human-heart experiments crammed into a small storage room at the hospital. In 2010, a sparkling new lab opened. It has two large freezers with human cells and human hearts, and a dozen stainless steel sinks containing pig hearts immersed in a colorless liquid.  Growing a heart is much harder than, say, growing a windpipe, because the heart is so big and has several types of cells, including those that beat, those that form blood vessels, and those that help conduct electrical signals. For a long time, scientists didn’t know how to make all the cells grow in the right place and in the right order.

The problem had been cracked by Dr. Taylor. She said that when human stem cells were put into a heart scaffold in 2010, they seemed to know just where to go. “They organized themselves in a way I didn’t believe,” said Dr. Taylor, who now works at the Texas Heart Institute but makes regular visits to Madrid to help with the experiments. “It’s amazing that the [scaffold] can be as instructional as it is. Maybe we don’t need to micromanage every aspect of this.”

Dr. Aviles said he hopes to have a working, lab-made version ready in five or six years, but the regulatory and safety hurdles for putting such an organ in a patient will be high. The most realistic scenario, he said, is that “in about 10 years” his lab will be transplanting heart parts.

He and his team already have grown early-stage valves and patches that could be used some day to repair tissue damaged by heart attack..  The Madrid lab has made only baby steps toward its grand plan to grow a human heart using the same techniques that Dr. Taylor pioneered with a rat heart.

“We opened the door and showed it was possible,” she said. “This is no longer science-fiction. It’s becoming science.”

A version of this article appeared March 22, 2013, on page A1 in the U.S. edition of The Wall Street Journal, with the headline: Science Fiction Comes Alive As Researchers Grow Organs in Lab.

FIGHTING LUNG DISEASE IN THE TINIEST PATIENTS

In ALL ARTICLES, SCIENCE & STEM CELLS on January 6, 2013 at 4:54 pm

Pbroncho

  1. Stem cells called mesenchymal stromal cells (MSCs) from a human umbilical cord (not the blood) have a protective effect on the lungs when injected into the lungs as they were put on oxygen.
  2. MSCs had a reparative effect when injected two weeks after being on oxygen.
  3. When conditioned media — a cell-free substance produced by MSCs — was administered instead of MSCs, it was found to have the same protective and reparative effects as the stem cells.
  4. When examined after six months (the equivalent of 40 human years), treated animals had better exercise performance and persistent benefit in lung structure.
  5. MSCs did not adversely affect the long-term health of normal rats. One of the concerns about stem cells is that by promoting cell growth, they may cause cancerous growth. To address this question, Dr. Thébaud gave MSCs to a control group that was not treated with oxygen. When examined after six months, these animals were normal and healthy.
SSSSSSSSSSSSSSSSSSSSSSSSSSSS
Five Big Strides to Fight Lung Disease in the Tiniest Patients

Dec. 4, 2012 — For Ottawa scientist and neonatologist Dr. Bernard Thébaud, even a major paper that answers five significant questions still doesn’t seem quite enough in his determined path to get his laboratory breakthrough into the neonatal intensive care unit (NICU). Dr. Thébaud’s proposed therapy would use stem cells from umbilical cords to treat a disease previously thought to be untreatable — bronchopulmonary dysplasia, or BPD.


“BPD is a lung disease described 45 years ago in which we have made zero progress. And now, with these cord-derived stem cells there is a true potential for a major breakthrough,” says Dr. Thébaud, a senior scientist at the Ottawa Hospital Research Institute and CHEO Research Institute, a neonatologist at CHEO and The Ottawa Hospital, and a professor in the Faculty of Medicine at the University of Ottawa.

“I am confident that we have the talent and the tools here at CHEO and OHRI to find a treatment for BPD. These findings published today are helping us get there,” continues Thébaud.

BPD affects approximately 10,000 very premature newborns in Canada and the U.S. every year. The lungs of these infants are not developed enough to sustain them, so they must receive oxygen through a breathing machine. However, this combination of mechanical ventilation and oxygen damages the lungs and stops their development. In addition, longer stays in the NICU for these extremely premature babies affect the normal development of other parts of the body, including the retina, the kidneys and the brain.

Today in the journal Thorax, Dr. Thébaud’s team provides significant findings in experiments with newborn rats given oxygen. The lung development of a newborn rat mimics that of a premature baby born at 24 weeks. The five major findings reported in Thorax are:

  1. Stem cells called mesenchymal stromal cells (MSCs) from a human umbilical cord (not the blood) have a protective effect on the lungs when injected into the lungs as they were put on oxygen.
  2. MSCs had a reparative effect when injected two weeks after being on oxygen.
  3. When conditioned media — a cell-free substance produced by MSCs — was administered instead of MSCs, it was found to have the same protective and reparative effects as the stem cells.
  4. When examined after six months (the equivalent of 40 human years), treated animals had better exercise performance and persistent benefit in lung structure.
  5. MSCs did not adversely affect the long-term health of normal rats. One of the concerns about stem cells is that by promoting cell growth, they may cause cancerous growth. To address this question, Dr. Thébaud gave MSCs to a control group that was not treated with oxygen. When examined after six months, these animals were normal and healthy.

Within two years, Dr. Thébaud wants to be talking about a pilot study with 20 human patients showing that this stem-cell therapy is feasible and safe, and in four years he wants to embark on a randomized control trial. These are all steps in his profound desire to help the babies he sees in the NICU with BPD, and he is confident a treatment will be developed.

“It’s going to happen here in Ottawa, but for babies worldwide,” says Dr. Thébaud.

CHRISTOPHER REEVE’S STEM CELL SPINAL CORD MISTAKE

In CELEBRITIES & STEM CELLS, STEM CELLS IN THE NEWS on September 25, 2012 at 1:07 pm

spinal

A SAD BIRTHDAY FOR CHRISTOPHER REEVE

Christopher Reeve would most likely have reached his 60th birthday today had he focused on adult stem cell treatments instead of embryonic.

Adult stem cell treatments have produced significant therapeutic benefits in Spinal cord injury patients for years.  Patients have regained sensation in the extremities, bladder and bowel control and even the ability to walk.  It is sad that a misinformed or misguided and certainly limited focus on embryonic stem cells resulted in the loss of potential for this iconic actor to recover from spinal cord injury.

HISTORY OF STEM CELL TREATMENTS FOR SPINAL CORD INJURY

SPINAL CORD INJURY vs ASC HISTORY OF TREATMENT – http://tinyurl.com/SCIvsASC

REGENERATING THE CENTRAL NERVOUS SYSTEM  http://repairstemcell.wordpress.com/2011/10/17/regenerating-the-central-nervous-system/

Stepping Towards A Paralysis Cure, A Tale Of Two Supermen Stem Cells Cure 23 Year Old Male of Paralysis – C6…-C7 injury
http://repairstemcell.wordpress.com/2009/03/28/stepping-towards-a-paralysis-cure-a-tale-of-two-supermen-stem-cells-cure-23-year-old-male-of-paralysis-c6-c7-injury/

Paraplegic – Adult Stem Cell Success Stories – Laura Dominguez
http://repairstemcell.wordpress.com/2010/05/05/paraplegic-adult-stem-cell-success-stories-laura-dominguez/

PARALYZED COUSINS PLEASED WITH STEM CELL TREATMENT
http://repairstemcell.wordpress.com/2010/02/15/paralyzed-cousins-pleased-with-stem-cell-treatment/

Successful Stem Cell Treatment of Spinal Cord Injury in Dogs
http://repairstemcell.wordpress.com/2010/02/08/successful-stem-cell-treatment-of-spinal-cord-injury-in-dogs/

Spinal Cord Injury Patient Wins…and Loses
http://repairstemcell.wordpress.com/2010/02/08/spinal-cord-injury-patient-wins-and-loses/

STEM CELLS FOR SPINAL CORD INJURY
http://repairstemcell.wordpress.com/2009/12/31/stem-cells-for-spinal-cord-injury/

Adult Stem Cell Grafts Help Paralyzed Heal
http://repairstemcell.wordpress.com/2009/10/21/adult-stem-cell-grafts-help-paralyzed-heal/

Medical hope as paralysed dog cured by stem cell therapy – mirror.co.ukhttp://repairstemcell.wordpress.com/2009/10/08/medical-hope-as-paralysed-dog-cured-by-stem-cell-therapy-mirror-co-uk/

Major the Roseville police dog gets stem cell treatment - http://blogs.citypages.com/blotter/2011/01/major_police_dog_stem_cell.php

 

http://www.myhero.com/ReadingRoom/books/Christopher%20Reeve%20-%20Nothing%20Is%20Impossible.jpg

Christopher D’Olier Reeve[1] (September 25, 1952 – October 10, 2004) was an American actor, film director, producer, screenwriter, author and activist. He achieved stardom for his acting achievements, in particular his motion-picture portrayal of the fictional superhero Superman.

On May 27, 1995, Reeve became a quadriplegic after being thrown from a horse during an equestrian competition in Virginia. He required a wheelchair and breathing apparatus for the rest of his life. He lobbied on behalf of people with spinal-cord injuries and for human embryonic stem cell research, founding the Christopher Reeve Foundation and co-founding the Reeve-Irvine Research Center.[2]

Cord Blood Treatment May Fulfill Baseballer’s Dreams

In STEM CELLS IN THE NEWS on April 13, 2012 at 11:29 am

Twenty-two-years ago, a doctor performed the first umbilical cord transplant for leukemia in the U.S. He used stem cells from a newborn’s umbilical cord and found that they could clean up leukemia cells…Ten years later, in 2000, he learned that mixing cord blood from two different babies was even more effective. Now, he’s taking it a step further.  “What makes this particularly unique is that Derrick is the first person in the world to receive this therapy,” said Wagner.

http://www.mommymdguides.com/wp-content/uploads/2010/09/QuestionsSecondTrimesterCordBloodBanking2.jpg

gee I hope Texas rules in favor of stem cell treatments today or all of the leukemia patients who follow this guy will be screwed.  they will have to enter a clinical trial in 6 years or so with 30% chance of receiving the cord blood, made into a drug with side effects of course…a trial which excludes anyone with anything else wrong with them (do leukemia patients ever have other sicknesses? probably not.  i seem to remember hearing a lot: “he’s healthy as an ox…except for the leukemia of course). 

so this is good news.  in 10 years or so all you leukemia patients can get a drug…made from cord blood stem cells…with a fraction of the effectiveness…and lots of negative side effects…maybe…

because the truth is, if it’s that rare, then the market sales will not be large enough to pay back the 1/2 billion required to bring the drug to market – so it will never get made anyway…and wait, 10 years?  what’s the life expectancy for  “high-risk form(s) of leukemia which [can] not be cured by chemotherapy?”  never mind readers. skip this article, this doesn’t apply to you.  you’ll all be dead by then.

I REALLY hope Texas rules in favor of stem cell treatments today

Cord Blood Treatment May Fulfill Baseballer’s Dreams

VIDEO – http://minnesota.cbslocal.com/video?autoStart=true&topVideoCatNo=default&clipId=6824750

MINNEAPOLIS (WCCO) — He was set to go to college last fall and play baseball, but leukemia changed that. Now, an 18-year-old man is part of the first-of-its-kind treatment that may allow him to fulfill his dream.

Derrick Keller is supposed to be playing baseball for Southwest Minnesota State University, not sitting in a hospital bed at University of Minnesota Amplatz Children’s Hospital. But last summer, just before he was set to leave for college on a baseball scholarship, Derrick began feeling weak.

“For no reason just jogging to centerfield and back, playing catch, my muscles would get extremely tired and I wasn’t feeling myself,” said Keller.

A blood test confirmed his family’s worst fears. Keller had a high-risk form of leukemia which could not be cured by chemotherapy.

“It was unexpected. I would never expect to hear that news. I was normal and it was just weird, I guess,” said Keller.

College was no longer an option. Neither was baseball, which was probably the hardest thing for Keller. But after months in and out of the hospital, his luck was about to change.

“We were able to show that cord blood was a very effective way of curing leukemia,” said Dr. John Wagner, who believes he may be able to cure Keller.

Twenty-two-years ago, Wagner performed the first umbilical cord transplant for leukemia in the U.S. He used stem cells from a newborn’s umbilical cord and found that they could clean up leukemia cells.

Ten years later, in 2000, he learned that mixing cord blood from two different babies was even more effective. Now, with Keller, he’s taking it a step further.

“What makes this particularly unique is that Derrick is the first person in the world to receive this therapy,” said Wagner.

Wagner says Keller would receive an expanded number of stem cells, beyond anything they’ve done before. On Feb. 7, Keller received 73 times more stem cells than the average patient gets.

Wagner’s theory is that the more stem cells Keller receives, the quicker the recovery time and less hospital visits down the road. The surgery was a success and, so far, Keller looks and feels better.

“We think we should be able to cure him of leukemia where, six months from now, you had no idea he ever went through a transplant,” said Wagner.

That would make him a part of history. For Keller, the thought of going to college and being able to play the sport he loves is more thrilling than all of his home runs combined.

“It gets tough sitting here when all my friends are off at college doing that kind of stuff. As soon as I can get back to playing ball and being the normal me again, it will feel great,” said Keller.

Wagner says, if successful, this treatment could be used for both children and adults.

If Keller continues to heal as fast as he is, Wagner sees no reason he can’t go to Southwest Minnesota State in Marshall this fall, where a baseball scholarship is still waiting for him.

Cord Blood Treatment May Fulfill Baseballer’s Dreams « CBS Minnesota.

FDA APPROVES FIRST CORD BLOOD PRODUCT

In STEM CELLS IN THE NEWS on April 6, 2012 at 2:06 am

Finally some good news!  I guess its true, even monkeys fall out of trees sometimes!

http://mymommymanual.com/wp-content/uploads/2009/10/cord-blood-300x225.png

FDA APPROVES FIRST CORD BLOOD PRODUCT

The U.S. Food and Drug Administration today approved HEMACORD, the first licensed hematopoietic progenitor cells-cord (HPC-C) cell therapy.

HEMACORD is indicated for use in hematopoietic stem cell transplantation procedures in patients with disorders affecting the hematopoietic (blood forming) system. For example, cord blood transplants have been used to treat patients with certain blood cancers and some inherited metabolic and immune system disorders.

“The use of cord blood hematopoietic progenitor cell therapy offers potentially life-saving treatment options for patients with these types of disorders,” said Karen Midthun, M.D., director, FDA’s Center for Biologics Evaluation and Research.

HEMACORD contains hematopoietic progenitor cells (HPCs) from human cord blood. Cord blood is one of three sources of HPCs used in transplants; the other two are bone marrow and peripheral blood..

Read more: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm279575.htm.

ADULT Stem Cell Therapy Reverses Diabetes – CBS 42

In VICTORIES & SUCCESS STORIES on January 18, 2012 at 9:12 am

ADULT Stem Cell Therapy Reverses Diabetes

BIRMINGHAM, Ala. (Ivanhoe Newswire)- Type 1 diabetes is caused by the body’s own immune system attacking its pancreatic islet beta cells and requires daily injections of insulin to regulate the patient’s blood glucose levels.

A new method found in the BioMed Central’s open access journal BMC Medicine uses stem cells from cord blood to reeducate the T cells in a diabetic’s blood to restart the pancreatic function and reduce the need for insulin. In Stem Cell Educator therapy, lymphocytes were separated from a patient’s blood over immobilized donated cord blood stem cells. After two or three hours in the device the revamped lymphocytes are returned to the patient. Progress was checked at 4, 12, 24 and 40 weeks after therapy.

After 12 weeks results showed an increase in C-peptide levels. C-peptide is a protein fragment created from insulin that can be used to determine how well beta cells are working. Levels increased at 24 weeks and remained the same at the end of the study, meaning that the patient’s daily dose of insulin could be reduced. Also results showed that the glycated hemoglobin (HbA1C) indicator of long term glucose control also dropped for people receiving the treatment.

Dr Yong Zhao, from University of Illinois at Chicago, was quoted as saying, “We also saw an improved autoimmune control in these patients. Stem Cell Educator therapy increased the percentage of regulatory T lymphocytes in the blood of people in the treatment group. Other markers of immune function, such as TGF-beta1 also improved. Our results suggest that it is this improvement in autoimmune control, mediated by the autoimmune regulator AIRE in the CBSC, which allows the pancreatic islet beta cells to recover.”

Source: BMC Medicine, January 2012

Stem Cell Therapy Reverses Diabetes – CBS 42 Birmingham, AL News Weather Sports.

Follow

Get every new post delivered to your Inbox.

Join 2,995 other followers

%d bloggers like this: